LFMD
$4.44
LifeMD, Inc.
Intraday
Recent News
A Look At LifeMD (LFMD) Valuation After Profitability Return And 2026 Growth Guidance
LifeMD (LFMD) is back on investors’ radar after reporting Q4 and full year 2025 earnings, swinging to net income and pairing those results with fresh 2026 revenue guidance and product expansion updates. See our latest analysis for LifeMD. That earnings swing and new 2026 guidance have come after a sharp rebound in the share price, with a 31.17% 7 day share price return and 29.02% 30 day share price return, even though the 1 year total shareholder return remains down 30.48%. If LifeMD’s recent...
LifeMD Inc (LFMD) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
LifeMD Inc (LFMD) reports robust financial performance with a 25% annual revenue increase and strategic advancements in AI and healthcare services.
LifeMD Q4 Earnings Call Highlights
LifeMD (NASDAQ:LFMD) executives highlighted strong fourth-quarter and full-year 2025 performance and outlined investment priorities for 2026, pointing to accelerating demand in its weight management business, expansion into women’s health, and continued momentum in men’s health. Management said the
LifeMD, Inc. (LFMD) Reports Q4 Loss, Tops Revenue Estimates
LifeMD (LFMD) delivered earnings and revenue surprises of -300.00% and +5.92%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Medifast Q4 Earnings Call Highlights
Medifast (NYSE:MED) reported fourth-quarter and full-year 2025 results while outlining continued efforts to reposition the business around metabolic health, highlighting early signs of improving coach productivity even as revenue and the active earning coach base declined sharply. Leadership transi